Basics Editas Medicine, Inc. Editas Medicine Inc is a genome editing company which is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. IPO Date: February 3, 2016 Sector: Healthcare Industry: Biotech Market Cap: $138.13M Activated in VL: True Average Daily Range Avg Daily Range: $0.73 | 3.34% Avg Daily Range (30 D): $0.08 | 5.00% Avg Daily Range (90 D): $0.10 | 6.09% Institutional Daily Volume Avg Daily Volume: 1.24M Avg Daily Volume (30 D): 1.59M Avg Daily Volume (90 D): 2.88M Trade Size Avg Trade Size (Sh.): 106 Avg Trade Size (Sh.) (30 D): 266 Avg Trade Size (Sh.) (90 D): 301 Institutional Trades Total Inst.Trades: 3,795 Avg Inst. Trade: $2M Avg Inst. Trade (30 D): $.87M Avg Inst. Trade (90 D): $.77M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.79M Avg Closing Trade (30 D): $.89M Avg Closing Trade (90 D): $.73M Avg Closing Volume: 159.76K         News Mar 6, 2025 @ 6:00 PM Global Genome Editing Market to Grow Rapidly at a ... Source: Delveinsight Feb 21, 2025 @ 6:00 PM Cell and Gene Therapies in Rare Disorders Market t... Source: Delveinsight Sep 10, 2024 @ 8:51 AM Gene Editing Therapeutics Market Forecast 2024-202... Source: Researchandmarkets.Com Aug 30, 2024 @ 12:59 PM Gene Therapy Market Size to Reach USD 54.39 Billio... Source: Sns Insider Aug 28, 2024 @ 1:00 PM Editas Medicine to Participate in Upcoming Investo... Source: N/A Financials   TTM Q1 2025 Q4 2024 Basic EPS $-3.04 $-.92 $-.55 Diluted EPS $-3.04 $-.92 $-.55 Revenue $ 35.84M $ 4.66M $ 30.6M Gross Profit $ $ $ Net Income / Loss $ -251.23M $ -76.09M $ -45.4M Operating Income / Loss $ -260.33M $ -76.16M $ -46.59M Cost of Revenue $ $ $ Net Cash Flow $ 69.47M $ 7.15M $ 35.71M PE Ratio